Inventor
SCHOLLER JOHN
US23 patents
⚠️ This page may combine multiple inventors who share the name “SCHOLLER JOHN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UNIV PENNSYLVANIA
14 patentsUS10040846B2Aug 7, 2018
Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer
UNIV PENNSYLVANIA39 citations97
US9783591B2Oct 10, 2017
Use of the CD2 signaling domain in second-generation chimeric antigen receptors
UNIV PENNSYLVANIA33 citations96
US9365641B2Jun 14, 2016
Compositions and methods for targeting stromal cells for the treatment of cancer
UNIV PENNSYLVANIA54 citations94
US9714278B2Jul 25, 2017
Use of ICOS-based CARs to enhance antitumor activity and CAR persistence
UNIV PENNSYLVANIA34 citations93
US11597754B2Mar 7, 2023
Use of the CD2 signaling domain in second-generation chimeric antigen receptors
UNIV PENNSYLVANIA4 citations84
US11299536B2Apr 12, 2022
Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer
UNIV PENNSYLVANIA5 citations83
US10800840B2Oct 13, 2020
Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer
UNIV PENNSYLVANIA4 citations83
US10501519B2Dec 10, 2019
Use of the CD2 signaling domain in second-generation chimeric antigen receptors
UNIV PENNSYLVANIA6 citations82
US12234274B2Feb 25, 2025
Use of the CD2 signaling domain in second-generation chimeric antigen receptors
UNIV PENNSYLVANIA1 citations73
US10577407B2Mar 3, 2020
Use of ICOS-based CARS to enhance antitumor activity and CAR persistence
UNIV PENNSYLVANIA3 citations72
US12350334B2Jul 8, 2025
Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer
UNIV PENNSYLVANIA0 citations62
US11958892B2Apr 16, 2024
Use of ICOS-based cars to enhance antitumor activity and car persistence
UNIV PENNSYLVANIA0 citations61
US11718685B2Aug 8, 2023
Compositions and methods for targeting stromal cells for the treatment of cancer
UNIV PENNSYLVANIA0 citations59
US10329355B2Jun 25, 2019
Compositions and methods for targeting stromal cells for the treatment of cancer
UNIV PENNSYLVANIA0 citations48
NOVARTIS AG
6 patentsUS10221245B2Mar 5, 2019
Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
NOVARTIS AG36 citations94
US10927184B2Feb 23, 2021
Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
NOVARTIS AG10 citations86
US10308717B2Jun 4, 2019
Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
NOVARTIS AG4 citations83
US11028177B2Jun 8, 2021
Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
NOVARTIS AG4 citations73
US11865167B2Jan 9, 2024
Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
NOVARTIS AG2 citations72
US12559562B2Feb 24, 2026
Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
NOVARTIS AG0 citations62